November 17 - 20, 2019
Boston Marriott Copley Place
Abstract submission deadline: Thursday, September 5
Advance registration deadline: Monday, October 7
Accreditation Statement The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation StatementAACR has designated this live activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) CreditPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, Jan. 2, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.Statement of Educational Need, Target Audience, and Learning ObjectivesThe field of immunotherapy is one of the most promising in cancer research. Utilizing the body’s immune system to fight cancer is often safer and better tolerated than traditional cancer treatments such as chemotherapy and radiation. Study and understanding of the immune system’s response to cancer has increased exponentially over the past several years, and this has given rise to many breakthrough cancer treatments.
Types of immunotherapies include radio- or chemolabeled monoclonal antibodies (including checkpoint inhibitors); bispecific monoclonal antibodies; checkpoint immunomodulators such as PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of many cancers; adoptive cell transfer (including CAR T cell therapy); therapeutic vaccines for treatment and prevention; cytokines such as interleukins and interferons; and oncolytic viruses.
Current promising research includes the discovery of novel targets for CAR T-cell therapy; characterization of therapeutic protein targets; exploration of signaling pathways in search of personalized and combinatory therapeutic targets; next-generation genomics approaches to resolve tumor evolution and heterogeneity; smart design and personalization for enhanced vaccines better able to infiltrate tumors; and new techniques to enhance immune response and recruitment to the tumor microenvironment, all geared towards a deeper understanding of the cancer cell in order to design better treatments. Research is also being conducted to understand and combat immune-related adverse events (IRAEs), such as autoimmunity, neurotoxicity, and cardiovascular toxicities.
This conference will feature some of the world’s premier oncologists who will present their latest research on current immunotherapies. It will also help bridge the gap between the advances that are underway in the lab and their application to clinical practice. Particularly, this conference will feature talks from scientists working in cutting edge fields such as engineered immune cells, imaging, and epigenomics; as well as new perspectives on tumor evolution and heterogeneity, the microbiome, and signaling pathways relevant to immune-oncology, which will lead to a deeper understanding of the immune response to cancer.
Only through a thorough understanding of the basic immunological science behind these new technologies and collaboration between basic scientists and oncologists can new treatments be developed. For physicians to best aid patients, they must have a solid and current understanding of the complexities of basic immunotherapy and new advances taking place in the lab that can eventually be applied to the clinic. Physicians will leave this conference with knowledge of novel advancements in immunotherapy in the lab and the potential thereof for therapeutic applications.
After participating in this CME activity, physicians should be able to:
Disclosure StatementIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgment of Financial or Other SupportThis activity is supported by Professional Educational Grants and will be disclosed at the activity.
Questions about CME?Please contact the Office of CME at (215) 440-9300 or email@example.com.Top of page